title: Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies.
abstract: This work was aimed at determining the BoNT/A L-chain antigenic regions recognized by blocking antibodies in human antisera from cervical dystonia patients who had become immunoresistant to BoNT/A treatment. Antisera from 28 immunoresistant patients were analyzed for binding to each of 32 overlapping synthetic peptides that spanned the entire L-chain. A mixture of the antisera showed that antibodies bound to three peptides, L11 (residues 141-159), L14 (183-201) and L18 (239-257). When mapped separately, the antibodies were bound only by a limited set of peptides. No peptide bound antibodies from all the patients and amounts of antibodies bound to a given peptide varied with the patient. Peptides L11, L14 and L18 were recognized predominantly. A small but significant number of patients had antibodies to peptides L27 (365-383) and L29 (379-397). Other peptides were recognized at very low and perhaps insignificant antibody levels by a minority (15% or less) of patients or had no detectable antibody with any of the sera. In the 3-dimensional structure, antibody-binding regions L11, L14 and L18 of the L-chain occupy surface areas and did not correlate with electrostatic potential, hydrophilicity/hydrophobicity, or temperature factor. These three antigenic regions reside in close proximity to the belt of the heavy chain. The regions L11 and L18 are accessible in both the free light chain and the holotoxin forms, while L14 appears to be less accessible in the holotoxin. Antibodies against these regions could prevent delivery of the L-chain into the neurons by inhibition of the translocation.
authors.affiliation: Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX 77030, USA. matassi@bcm.edu
authors.forename: M Zouhair
authors.initials: MZ
authors.lastname: Atassi
authors.forename: Behzod Z
authors.initials: BZ
authors.lastname: Dolimbek
authors.forename: Joseph
authors.initials: J
authors.lastname: Jankovic
authors.forename: Lance E
authors.initials: LE
authors.lastname: Steward
authors.forename: K Roger
authors.initials: KR
authors.lastname: Aoki
mesh_terms: D000595:Amino Acid Sequence; D019138:Antibodies, Blocking / Q000378:metabolism; D019274:Botulinum Toxins, Type A / Q000276:immunology / Q000378:metabolism* / Q000627:therapeutic use; D004351:Drug Resistance; D018604:Epitope Mapping / Q000379:methods; D006801:Humans; D007106:Immune Sera / Q000378:metabolism; D016056:Immunodominant Epitopes / Q000276:immunology / Q000378:metabolism*; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000138:chemical synthesis / Q000276:immunology / Q000378:metabolism*; D011487:Protein Conformation; D014103:Torticollis / Q000188:drug therapy* / Q000276:immunology*
chemical_list: D019138:Antibodies, Blocking; D007106:Immune Sera; D016056:Immunodominant Epitopes; D010446:Peptide Fragments; D019274:Botulinum Toxins, Type A